Lazard Capital Downgrades Progenics Pharmaceuticals (PGNX) to Neutral
Tweet Send to a Friend
Lazard Capital downgraded Progenics Pharmaceuticals (NASDAQ: PGNX) from Buy to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
